Second Quarter 2024 Results / Half-Year Financial Report
Bayer Q2 2024 Media Update
Modest Performance in Challenging Agricultural Market Environment – Group outlook confirmed
- Group sales at 11.144 billion euros (Fx & portfolio adj. plus 3.1 percent)
- EBITDA before special items declines to 2.111 billion euros (minus 16.5 percent), impacted by currency headwinds
- Crop Science posts slight increase in sales and sharp fall in earnings
- Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
- Core earnings per share at 0.94 euros (minus 23.0 percent)
- Net income at minus 34 million euros
- Free cash flow at 1.273 billion euros
- Good progress on strategic priorities – advances in innovation, especially in the Pharmaceuticals Division
Strategy and Financial Update
Bayer CEO Bill Anderson shares an overview of where Bayer stands at the half-year mark – and what’s to come in the next 90 days.
Media Update Recording
Speaker
CFO of Bayer AG | CEO of Bayer AG |